Kuzoyan Vahe, President of an undisclosed company, has demonstrated a consistent pattern of selling shares in Titan Pharmaceuticals (TTAN) based on SEC Form 4 filings. With 86 total transactions, all have been sales, totaling over $23.2 million in aggregate value. The activity is concentrated exclusively in TTAN, with no recorded purchases across any securities. Recent filings show heightened selling in early 2026, including 22 discrete sales between January 5 and March 18. The transactions vary in size, ranging from smaller dispositions like a $2,681.90 sale on January 5 to larger blocks such as a $499,779.54 transaction the same day. March 18 alone saw 11 sales, with values spanning from $4,890.20 to $102,100.39.
The absence of any buying activity suggests a one-directional approach to insider transactions. While the sales are spread across multiple dates, the concentration in early 2026—particularly the cluster of mid-sized transactions in March—indicates an ongoing divestment strategy. The filings include several same-day transactions with varying dollar amounts, likely representing systematic sales rather than isolated disposals. Given the lack of purchases and the repeated selling pattern, Kuzoyan’s trading history reflects a sustained reduction in TTAN holdings over time. The reasons behind the sales are not disclosed in the filings, which strictly report the transactional details without commentary on intent.
AI-assisted summary